IP Library › Granted Patent US 12,485,168
Granted Patent B2
US 12,485,168 · App. 17/638,344 · Granted Dec 2, 2025

Hepatitis B virus vaccines

Inventors: Eric Bruening (San Francisco, CA); Janet Douglas (San Francisco, CA); Emily Marshall (San Francisco, CA); Karina Yusim (Santa Fe, NM); Bette Korber (Santa Fe, NM); James Theiler (Santa Fe, NM)
Assignees: Vir Biotechnlogy, Inc.; Triad National Security, LLC
A61K39/292A61P31/20C07K14/005C12N15/86A61K2039/5256A61K2039/53A61K2039/70C12N2710/16122C12N2710/16142C12N2730/10134
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,485,168
App. No.
17/638,344
Granted
Dec 2, 2025
Kind
B2
Abstract

Isolated polynucleotides and polypeptides, and hepatitis B virus (HBV) vaccines comprising the same. Viral vectors for expressing such polypeptides, and which may be used in HBV vaccines, as well as methods of protecting a subject from HBV infection and methods of treating HBV in a subject comprising administering the polypeptides, vectors, or vaccines. Methods of designing and producing an HBV vaccine comprising designing vaccine antigens to cover the diversity within a geographic area using an antigen amino acid sequence that efficiently covers the epitopes in the HBV genotypes present in the geographic area.

Claims (15)

1 . A polypeptide comprising the amino acid sequence as set forth in SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 14 15, 24, 25, or 26.

2 . A polypeptide comprising two or more of the amino acid sequences selected from SEQ ID NOs:1-11, 14, 15, and 24-26.

3 . The polypeptide of claim 1 , wherein the polypeptide comprises the amino acid sequence as set forth in SEQ ID NO:15, 24, 25, or 26.

4 . A cytomegalovirus (CMV) vector comprising a polynucleotide comprising the sequence encoding one or more amino acid sequences as set forth in SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 14, 15, 24, 25, or 26.

5 . The CMV vector of claim 4 , wherein the CMV vector is a human CMV (HCMV) vector or a rhesus CMV (RhCMV) vector.

6 . The CMV vector of claim 5 , wherein the CMV vector lacks the UL82 gene.

7 . The CMV vector of claim 5 , wherein the CMV vector lacks the UL128-UL130 gene region and lacks the UL146-UL147 gene region.

8 . The CMV vector of claim 5 , wherein the CMV vector has an intact UL128-UL130 gene region and an intact UL146-UL147 gene region.

9 . The CMV vector of claim 4 , wherein the one or more amino acid sequences comprise one or more of SEQ ID NOs:15, 24, 25, and 26.

10 . A hepatitis B virus (HBV) vaccine comprising one or more polypeptides according to claim 1 .

11 . A method of treating HBV in a subject comprising administering an effective amount of the vector of claim 4 to the subject in need thereof.

12 . A method of protecting a subject from an HBV infection comprising administering an effective amount of the vector of claim 4 to the subject in need thereof.

13 . A method of generating or inducing an immune response to HBV in a subject comprising administering an effective amount of the vector of claim 4 to the subject in need thereof.

14 . A method of generating or inducing an immune response to HBV in a subject comprising administering an effective amount of the polypeptide of claim 1 to the subject in need thereof.

15 . A method of generating or inducing an immune response to HBV in a subject comprising administering an effective amount of the vaccine of claim 10 to the subject in need thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 2, 2023
From: BRUENING, ERIC; DOUGLAS, JANET; MARSHALL, EMILY
To: VIR BIOTECHNOLOGY, INC.
Reel/Frame 065090/0104 →
Continuity (3)
Provisional Application 62941125 · Nov 27, 2019
Provisional Application 62893546 · Aug 29, 2019
Related Publication 20220288195A1 · Sep 15, 2022
References Cited (48)
US 6072049A · Thoma · 2000 [cited by applicant]
US 7018826B1 · Hildt et al. · 2006 [cited by applicant]
US 7875423B2 · Bartholomeusz et al. · 2011 [cited by applicant]
US 8278432B2 · Bozdayi · 2012 [cited by applicant]
US 8859198B2 · Bartholomeusz et al. · 2014 [cited by applicant]
US 9249427B2 · Picker et al. · 2016 [cited by applicant]
US 9393299B2 · Martin et al. · 2016 [cited by applicant]
US 10532099B2 · Picker et al. · 2020 [cited by applicant]
US 10894078B2 · Bruening et al. · 2021 [cited by applicant]
US 10912827B2 · Protzer et al. · 2021 [cited by applicant]
US 11091779B2 · Frueh et al. · 2021 [cited by applicant]
US 20040054139A1 · Page et al. · 2004 [cited by applicant]
US 20040106174A1 · Jones et al. · 2004 [cited by applicant]
US 20040137016A1 · Moon et al. · 2004 [cited by applicant]
US 20080171062A1 · Sala-Schaeffer · 2008 [cited by examiner]
US 20140106174A1 · Yamaguchi et al. · 2014 [cited by applicant]
US 20160106830A1 · Georges · 2016 [cited by examiner]
US 20180133321A1 · Picker · 2018 [cited by examiner]
US 20220257748A1 · Früh · 2022 [cited by examiner]
CA 3040225A1 · 2011 [cited by applicant]
KR 1020130113046A · 2013 [cited by applicant]
KR 101418836B1 · 2014 [cited by applicant]
WO 0127281A1 · 2001 [cited by applicant]
WO 0198333A2 · 2001 [cited by applicant]
WO 02094866A1 · 2002 [cited by applicant]
WO 2005042733A1 · 2005 [cited by applicant]
WO 2011015656A2 · 2011 [cited by applicant]
WO 2012109404A1 · 2012 [cited by applicant]
WO 2016054654A1 · 2016 [cited by applicant]
WO 2016130693A1 · 2016 [cited by applicant]
WO 2017121791A1 · 2017 [cited by applicant]
WO 2018075591A8 · 2018 [cited by applicant]
WO 2018189522A1 · 2018 [cited by applicant]
Caposio et al., “Characterization of a live-attenuated HCMV-based vaccine platform,” [cited by applicant]
Genbank, “Hepatitis B virus isolate M154, complete genome,” Accession No. GQ358158.1, Apr. 29, 2011. (3 pages). [cited by applicant]
Genbank, “Hepatitis B virus, complete genome,” Accession No. Y07587.1, Mar. 20, 2001. (3 pages). [cited by applicant]
Hansen et al., “Broadly targeted CD8+ T cell responses restricted by major histocompatibility complex E,” [cited by applicant]
Hansen et al., “Cytomegalovirus Vectors Violate CD8+ T Cell Epitope Recognition Paradigms,” [cited by applicant]
Hansen et al., “Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge,” [cited by applicant]
Hansen et al., “Evasion of CD8 [cited by applicant]
Hansen et al., “Immune clearance of highly pathogenic SIV infection,” [cited by applicant]
Hansen et al., “Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine,” [cited by applicant]
Korber, “LANL/New Mexico Consortium HIV vaccine design and Analysis,” Los Alamos National Laboratory, LA-UR-14-25023, Jul. 7, 2014, 10 pages. [cited by applicant]
Theiler et al., “Epigraph: A Vaccine Design Tool Applied to an HIV Therapeutic Vaccine and a Pan-Filovirus Vaccine,” [cited by applicant]
UniProt, “Hepatitis B virus (HBV),” sequence ID No. A0AOD3RZH3, downloaded Feb. 17, 2021. (3 pages). [cited by applicant]
UniProt, “Hepatitis B virus (HBV),” sequence ID No. B3VB42_HBV, downloaded Feb. 17, 2021. (2 pages). [cited by applicant]
UniProt, “Hepatitis B virus (HBV),” sequence ID No. K9UTJ3_HBV, downloaded Feb. 17, 2021. (1 page). [cited by applicant]
UniProt, “Hepatitis B virus (HBV),” sequence ID No. Q9IXD7_HBV, downloaded Feb. 17, 2021. (1 page). [cited by applicant]